In 2024, a Boston-based startup, NeuroPharm AI, presented a system capable of developing a new cancer drug molecule, testing it in a simulation, and proposing a clinical protocol in 48 hours. Previously, this process took 10-15 years and cost $2.6 billion. Now, it takes two days and costs $40,000. It is based on a hybrid neural network that combines deep learning models with quantum calculations of protein structure.
Advertising
The system analyzed 150 million known biological interactions and identified a pattern missed by humans: some tumors use “molecular decoys” to suppress the immune response. The AI proposed a molecule that blocks these decoys. The drug, called “ImunoKey,” has already completed Phase I clinical trials, with 98% of patients experiencing no side effects.
The key advantage is personalization. Artificial intelligence analyzes a patient’s genome, microbiome, and lifestyle to create a unique medicine. In 2025, the first “micropharm” opened in Switzerland—a garage-sized factory where AI controls drug synthesis in real time. A patient comes in the morning and leaves in the afternoon with a medicine created during their tea break.
The technology is already saving lives. In Japan, AI has developed a cure for a rare form of leukemia affecting children. Previously, the survival rate was 12%. After the new drug, it’s 89%. The WHO has included this approach in its global cancer program.
